After treatment with quadrigemine I (1.25 and 5 mg/kg), the inhibition rates for IL-6 were 20.95 ± 0.30% and 30.00 ± 0.86% in serum, 2.13 ± 1.99% and 22.91 ± 0.71% in liver tissue, 5.10 ± 0.62% and 25.33 ± 0.98% in spleen tissue, and 2.74 ± 0.40% and 14.17 ± 0.09% in tumor tissue. This evidence concerns the gene IL6 and neoplasm.